Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, Alla S Lisyanskaya, Sandro Pignata, Ignace Vergote, Francesco Raspagliesi, Gabe S Sonke, Michael Birrer, Diane M Provencher, Jalid Sehouli, Nicoletta Colombo, Antonio González-Martín, Ana Oaknin, P B Ottevanger, Vilius Rudaitis, Julie Kobie, Michael Nebozhyn, Mackenzie Edmondson, Yuan Sun, Razvan Cristescu, Petar Jelinic, Stephen M Keefe, Ursula A Matulonis
OBJECTIVE: This prespecified exploratory analysis evaluated the association of gene expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry (mIHC) tumor microenvironment-associated cell phenotypes with clinical outcomes of pembrolizumab in advanced recurrent ovarian cancer (ROC) from the phase II KEYNOTE-100 study. METHODS: Pembrolizumab-treated patients with evaluable RNA-sequencing (n = 317), whole exome sequencing (n = 293), or select mIHC (n = 125) data were evaluated...
October 18, 2023: Gynecologic Oncology